Leynadier F, Murrieta M, Dry J, Colin J N, Gillotin C, Steru D
Service de médecine interne-allergie, Hôpital Rothschild, Paris.
Ann Allergy. 1994 Jun;72(6):520-4.
The response to the histamine hydrochloride prick skin test was studied in 24 healthy volunteers who received, in random order and at least four days apart, acrivastine (8 mg), terfenadine (120 mg), and placebo. The tests were performed on either side of the back before and at the time of administration (single dose), then every 30 minutes for two hours, and every hour for the following four hours. Evaluation was based on the mean of two measurements of the surface area of the wheal-and-flare reaction accompanied by assessment of topical pruritus. The response to histamine was decreased markedly in the two active treatment groups. Although within one hour of injection, the activity of both antihistamines was consistently greater than that of placebo, the kinetics of action of the two products nevertheless differed; indeed acrivastine was active against flare and wheal earlier (within 30 minutes); terfenadine proved to be more active than acrivastine only on flare and only at the later times (four, five, and six hours). The safety study primarily demonstrated drowsiness in one-fourth of the patients receiving placebo and active treatment.
对24名健康志愿者进行了盐酸组胺点刺皮肤试验反应的研究，这些志愿者按随机顺序且间隔至少4天接受阿伐斯汀（8毫克）、特非那定（120毫克）和安慰剂。在给药前（单剂量）和给药时在背部两侧进行测试，然后在两小时内每30分钟进行一次，在接下来的四小时内每小时进行一次。评估基于风团和潮红反应表面积的两次测量平均值，并伴有局部瘙痒评估。两个活性治疗组对组胺的反应明显降低。虽然在注射后一小时内，两种抗组胺药的活性始终高于安慰剂，但两种产品的作用动力学仍有所不同；实际上，阿伐斯汀对潮红和风团的作用更早（在30分钟内）；特非那定仅在潮红方面且仅在较晚时间（4、5和6小时）比阿伐斯汀更具活性。安全性研究主要表明，接受安慰剂和活性治疗的患者中有四分之一出现嗜睡。
